10rx vs Oak
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, 10rx opens cheaper — $99.67/mo against $119, and Oak is where most people should begin. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
10rx
Compounded; GLP-1 options as low as under $100/mo
Compounded GLP-1 + GIP
Oak
Hero + product card: 'Semaglutide from $119' / 'Most Affordable Semaglutide As low as $119 /mo'. Old code OAKNEW50 no longer on site; a '$200 off — new patient offer' is advertised with no published terms or resulting price (quiz-gated), so promo price is not published. Site is internally inconsistent elsewhere ($133 meta description, $167 compare table, $190 on /weightloss) — hero pricing matches
Hero + product card: 'Tirzepatide from $185' / 'Most Popular Tirzepatide As low as $185 /mo'. Same flat 'One price · All dosages · No subscriptions' model; $200-off new-patient offer advertised without published mechanics — final checkout price quiz-gated, not published.
What’s included
10rx
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Oak
Covered by the monthly price
Medication
In the price
Clinician visits
Not stated
Shipping
In the price
Lab work
Not stated
Coaching
In the price
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
10rx
8.1/10
Oak
7.9/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | 10rx | Oak |
|---|---|---|
| Starting Price | ✓$99.67/mo | $119/mo |
| Features | ✓8 features | 4 features |
| States Available | Not disclosed | Not disclosed |
| Compounded | — | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
About 10rx
10rx sets flat monthly rates on compounded GLP-1: semaglutide at $99.67, tirzepatide at $149.67, with NAD+ and sermorelin sold separately for energy and recovery. A free health quiz online reaches a board-certified telehealth doctor, who reads your history before writing anything, and licensed pharmacy partners handle discreet delivery. The company states it reaches every one of the 50 states. What it does not state is its operating company, its pharmacies, or any terms page.
Read our full 10rx review →About Oak
Oak sells compounded semaglutide and tirzepatide through telehealth. Oak Longevity Holdings Corp. operates the business, and prescriptions are issued through NVP Medical Group, P.A.
Read our full Oak review →Pros & Cons
10rx
What we like
- Semaglutide at $99.67 a month, 47% below the $189 median for the same drug and form across this register
- Tirzepatide at $149.67 a month, 44% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Oak
What we like
- Semaglutide at $119 a month, 37% below the $189 median for the same drug and form across this register
- Tirzepatide at $185 a month, 31% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, shipping, coaching
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Oak is the one we would pick, particularly on semaglutide at $119/month, 37% under the register median. 10rx is a real alternative if semaglutide at $99.67/month, 47% under the register median is what you are after — the six-dimension breakdown and the prices below are what to weigh against your own case.
Choose 10rx if…
You want semaglutide at $99.67/month, 47% under the register median and an opening price near $99.67 a month.
Choose Oak if…
You want semaglutide at $119/month, 37% under the register median and an opening price near $119 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Trimi Health
Knowing which pharmacy fills the vial — it names VialsRx
From $99/mo
Get started →Strut Health
Semaglutide at $99/month, 48% under the register median
From $99/mo
Get started →Oak
Semaglutide at $119/month, 37% under the register median
From $119/mo
Get started →10rx vs Oak: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring 10rx and Oak head-to-heads in the same category.
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.